Suppr超能文献

建立世卫组织第 3 号国际凝血酶标准的国际合作研究:国际血栓与止血学会因子 XIII 和纤维蛋白原科学小组委员会的报告。

An international collaborative study to establish the WHO 3rd International Standard for Thrombin: Communication from the ISTH SSC subcommittee on factor XIII and fibrinogen.

机构信息

Haemostasis Section, Biotherapeutics Division, National Institute for Biological Standards and Control, South Mimms, UK.

Biostatistics Section, National Institute for Biological Standards and Control, South Mimms, UK.

出版信息

J Thromb Haemost. 2021 Mar;19(3):852-858. doi: 10.1111/jth.15207.

Abstract

The calibration of thrombin products relies on the World Health Organization (WHO) 2nd International Standard (IS) for Thrombin (01/580) which defines the international unit (IU) for thrombin potency. With stocks of the 2nd IS (01/580) running low, an international collaborative study was organized to calibrate a replacement. Twenty laboratories from 13 countries took part in the study and measured the potency of two candidate replacement standards (coded 01/578 and 19/188) relative to the 2nd IS. In total, 111 valid assays were returned, which were a combination of plasma/fibrinogen clotting assays and chromogenic assays. Variation between and within laboratories was low, with inter- and intra-laboratory geometric coefficient of variation (GCV) generally <5% for all assay methods and substrates. For 01/578, potency estimates by clotting assays (101.1 IU/ampoule) were significantly lower than estimates by chromogenic assays (111.5 IU/ampoule). Mean potency estimates for 19/188 were 90.4 IU/ampoule by clotting assay and 88.1 IU/ampoule by chromogenic assay, which was not a statistically significant difference. The close ratio between clotting and chromogenic assay potency estimates for 19/188 suggests it has a higher α-thrombin content than 01/578 and is equivalent to the current IS (01/580). Accelerated degradation studies predicted excellent long-term stability profiles for preparations 01/580, 01/578, and 19/188. Based on the results of this study, the WHO Expert Committee on Biological Standardization established 19/188 as the 3rd IS for Thrombin with a potency of 90 IU/ampoule in August 2020.

摘要

凝血酶产品的校准依赖于世界卫生组织(WHO)的第 2 国际标准(IS)凝血酶(01/580),该标准定义了凝血酶效价的国际单位(IU)。随着第 2 国际标准(01/580)库存的减少,组织了一项国际协作研究来校准替代品。来自 13 个国家的 20 个实验室参与了这项研究,并相对于第 2 国际标准(IS)测量了两种候选替代标准(编码为 01/578 和 19/188)的效价。总共返回了 111 份有效测定值,这些测定值是血浆/纤维蛋白原凝结测定和显色测定的组合。实验室之间和实验室内部的差异很小,所有测定方法和基质的实验室间和实验室内几何变异系数(GCV)通常均<5%。对于 01/578,凝结测定(101.1 IU/安瓿)的效价估计值明显低于显色测定(111.5 IU/安瓿)的效价估计值。19/188 的平均效价估计值通过凝结测定为 90.4 IU/安瓿,通过显色测定为 88.1 IU/安瓿,这没有统计学上的显着差异。19/188 的凝结和显色测定效价估计值之间的接近比值表明其α-凝血酶含量高于 01/578,并且与当前的 IS(01/580)等效。加速降解研究预测 01/580、01/578 和 19/188 制剂具有极好的长期稳定性。基于这项研究的结果,世界卫生组织生物标准化专家委员会于 2020 年 8 月将 19/188 确立为凝血酶的第 3 个 IS,效价为 90 IU/安瓿。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验